Kinji Iizuka

This inventor holds 19 USPTO granted patents. Top assignees: Kissei Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kissei Yakuhin Kogyo Kabushiki Kaisha. Active years: 1976-1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kinji Iizuka. Retrieved from https://idiyas.com/inventor/kinji-iizuka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 100.0

Average Co-Inventor Count = 5.1

ph-index = 7

Forward Citations = 222(Granted Patents)

Location History:

Nagoya, JA (1977)
Matsumoto, JA (1976 - 1978)
Matsumoto, JP (1980 - 1986)
Kanbayashi, JP (1986)
Nagano, JP (1984 - 1989)

Company Filing History:

16 out of 176

Kissei Pharmaceutical Co., Ltd.

patents

6 out of 575

Ono Pharmaceutical Co., Ltd.

patents

1 out of 1

Kissei Yakuhin Kogyo Kabushiki Kaisha

patent

4. 1 out of 1

Kissei Yakuhin Kogyo Kabushiki Kaisha (Kissei Pharmaceutical Co. Ltd.)

patent

where one patent can have more than one assignee

Years Active: 1976-1989

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4870183 - Novel amino acid derivatives (1989-09-26),

2. 4863904 - Dipeptides as renin inhibitors (1989-09-05),

3. 4857650 - Novel renin inhibitory amino acid derivatives (1989-08-15),

4. 4853463 - Amino acid derivatives (1989-08-01),

5. 4841067 - Novel amino acid derivatives (1989-06-20),

6. 4711958 - Morpholine containing amino acid derivatives (1987-12-08),

7. 4656269 - Histidine derivatives (1987-04-07),

8. 4632934 - Imidazole derivatives and pharmaceutical use thereof (1986-12-30),

9. 4623724 - Method for the production of nuclear substituted cinnamoylanthranilic (1986-11-18),

10. 4607046 - 4-(1-imidazolylmethyl)cinnamic acid hydrochloride monohydrate and (1986-08-19),

11. 4587356 - Process for the production of nuclear substituted cinnamoylanthranilic (1986-05-06),

12. 4486597 - Method for the production of nuclear substituted cinnamoylanthranilic (1984-12-04),

13. 4469865 - 1,3-Disubstituted imidazoles (1984-09-04),

14. 4461905 - Imidazole derivatives (1984-07-24),

15. 4320134 - Inhibiton of thromboxane synthetase with 1-substituted imidazole (1982-03-16),

Title: **The Innovative Contributions of Kinji Iizuka**

Introduction

Kinji Iizuka is a prominent inventor based in Nagano, Japan, known for his remarkable contributions to the field of pharmaceuticals. With a total of 19 patents to his name, Iizuka has been instrumental in developing novel therapeutic agents that address critical health issues, particularly in the realm of hypertension.

Latest Patents

Among his latest innovations are the following patents:

1. **Novel Amino Acid Derivatives** - This patent discloses novel amino acid derivatives useful as therapeutic agents. These compounds exhibit a human renin inhibitory effect when administered orally, making them effective for the treatment of hypertension, especially in cases associated with renin.

2. **Dipeptides as Renin Inhibitors** - In this patent, Iizuka describes dipeptides represented by a specific formula. These compounds show a strong inhibitory effect on human renin and are highly valued as therapeutically active agents for treating hypertension, particularly renin-associated hypertension.

Career Highlights

Throughout his career, Kinji Iizuka has collaborated with several noteworthy companies, including Kissei Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. His work at these organizations has paved the way for many advancements in hypertension treatment, showcasing his significant impact on the pharmaceutical industry.

Collaborations

Kinji Iizuka has worked alongside notable colleagues such as Tetsuhide Kamijo and Kenji Akahane. Their collective expertise in pharmacology and medicine has contributed to successful research and the eventual development of innovative therapeutic agents.

Conclusion

In summary, Kinji Iizuka stands out as a highly influential inventor whose work has made substantial contributions to medical science, particularly in developing novel treatments for hypertension. His patents reflect a commitment to improving health outcomes, and his collaborations underscore the importance of teamwork in achieving breakthroughs in pharmaceutical innovations.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]